Recent Updates
Recently added Catalysts
SRTS Negative Sentiment

Sensus Healthcare, Inc. Investors: Company Investigated by the Portnoy Law Firm

Key Takeaway: The Portnoy Law Firm has initiated an investigation into possible securities fraud related to Sensus Healthcare, Inc. (SRTS) and may file a class action lawsuit on behalf of investors. This comes after Sensus reported disappointing financial results for Q2 2025, including a significant loss per share and a sharp decline in revenue. Following the announcement, Sensus's stock price fell by over 35%, prompting concerns among investors regarding potential losses.
Price reaction · baseline $3.18 (2025-08-27 close) · hit after-hours · 1 other SRTS headline(s) in the window, move may be shared
day 0 close · peak
+3.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • Sensus reported a GAAP earnings-per-share loss of $0.06, missing estimates.
  • Revenue declined 20.7% year-over-year and fell short of estimates by $2 million.
  • The stock price dropped approximately 35.3% following the financial results announcement.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sensus Healthcare, Inc. (“Sensus” or “the Company”) (NASDAQ: SRTS) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Sensus investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On August 7, 2025, Sensus reported its financial results for the second quarter of 2025, disclosing a GAAP earnings-per-share loss of $0.06, missing analyst estimates by $0.09, and revenue of $7.3 million, a decline of 20.7% year-over-year and below estimates by $2 million. Sensus attributed the revenue decline primarily to a reduction in units sold to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements.
On this news, the price of Sensus stock declined $1.89 per share, or approximately 35.3%, to close at $3.46 per share on August 8, 2025, thereby injuring investors.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
Attorney Advertising

Frequently Asked Questions

How can Sensus investors recover their losses?

Investors can contact the Portnoy Law Firm for a free case evaluation regarding their losses.

What initiated the investigation into Sensus Healthcare?

The investigation began due to potential securities fraud after Sensus's poor financial results.

Who to contact for legal rights regarding Sensus losses?

Investors can reach out to attorney Lesley Portnoy via phone or email for assistance.

What was Sensus's reported earnings for Q2 2025?

Sensus reported a GAAP EPS loss of $0.06, missing estimates by $0.09.

What caused Sensus's revenue decline?

The decline was mainly due to reduced sales to a large customer, despite some growth in recurring revenue.

Last updated: Aug 28, 2025